INT272415

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 17.62
Pain Relevance 0.73

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
eyes 6
NARFL (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 22 99.90 Very High Very High Very High
agonist 33 99.58 Very High Very High Very High
Serotonin 51 99.40 Very High Very High Very High
Inflammation 37 98.76 Very High Very High Very High
Onset of action 2 92.80 High High
headache 18 62.36 Quite High
anesthesia 37 56.48 Quite High
corticosteroid 4 15.88 Low Low
Spinal cord 3 8.32 Low Low
metalloproteinase 35 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Ocular Hypertension 1377 100.00 Very High Very High Very High
Glaucoma 345 99.84 Very High Very High Very High
Uveitis 55 98.84 Very High Very High Very High
INFLAMMATION 40 98.76 Very High Very High Very High
Hypotension 66 95.08 Very High Very High Very High
Low Tension Glaucoma 21 92.04 High High
Toxicity 9 92.00 High High
Endophthalmitis 1 81.12 Quite High
Cataract 30 78.80 Quite High
Acquired Immune Deficiency Syndrome Or Hiv Infection 1 78.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Subsequent surgical treatment was needed in 7 of the 40 (4.7%) to reduce high IOP levels that were refractory to maximal medical therapy with 2 or 3 antiglaucomatous drugs.
Negative_regulation (reduce) of Gene_expression (levels) of IOP associated with ocular hypertension
1) Confidence 0.34 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698684 Disease Relevance 1.40 Pain Relevance 0
Dorzolamide/timolol fixed combination (DTFC) was found to be as effective as the concomitant administration of its components in reducing IOP and has also simplified the therapy for patients needing these two medications (Boyle et al 1991).
Negative_regulation (effective) of Gene_expression (reducing) of IOP associated with ocular hypertension
2) Confidence 0.34 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698680 Disease Relevance 1.46 Pain Relevance 0.06
Most of the oxybuprocaine subjects presented with an IOP change within Ā±2 mmHg (of the initial IOP) after instillation of the eyedrops, with approximately 87% (two minutes and five minutes post eyedrop instillation) showing an IOP change that ranged from +1 mmHg to ?
Negative_regulation (presented) of Gene_expression (change) of IOP associated with ocular hypertension
3) Confidence 0.23 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701119 Disease Relevance 1.17 Pain Relevance 0
Although most subjects in all three groups had IOP changes between ?
Negative_regulation (had) of Gene_expression (changes) of IOP associated with ocular hypertension
4) Confidence 0.23 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701119 Disease Relevance 0.72 Pain Relevance 0.06
Almost all the subjects in this group presented with an IOP change between +1 mmHg and ?
Negative_regulation (presented) of Gene_expression (change) of IOP associated with ocular hypertension
5) Confidence 0.23 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701119 Disease Relevance 1.24 Pain Relevance 0
DorzolamideĀ–timolol was also found to reduce the mean IOP fluctuations over the 12 hours from 8.6 mmHg down to 4.3 mmHg (P < 0.0001).46
Negative_regulation (reduce) of Gene_expression (fluctuations) of IOP associated with ocular hypertension
6) Confidence 0.09 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2993108 Disease Relevance 1.21 Pain Relevance 0
A large number of reports have shown that serotonin agonists and antagonists can produce increases and decreases in IOP when given orally, topically to the eye or when they are directly injected in the anterior chamber [10, 26, 34, 35, 64, 75, 84, 87, 88, 112, 113, 126, 136, 137].
Negative_regulation (decreases) of Gene_expression (produce) of IOP in eye associated with antagonist, agonist, ocular hypertension and serotonin
7) Confidence 0.06 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2701282 Disease Relevance 0.49 Pain Relevance 0.43
However, its effectiveness in IOP reduction in glaucoma associated with uveitis or neovascularization is probably questionable in addition to the possibility of aggravation of inflammation.
Negative_regulation (effectiveness) of Gene_expression (reduction) of IOP associated with inflammation, glaucoma, uveitis and ocular hypertension
8) Confidence 0.05 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701126 Disease Relevance 2.04 Pain Relevance 0.08
Although PGs are shown to be effective in IOP reduction for chronic angle closure glaucoma, its effectiveness is unreliable if a quick reduction of IOP is desirable such as in acute angle closure attack, because of its relatively slow onset of action.


Negative_regulation (effective) of Gene_expression (reduction) of IOP associated with onset of action, glaucoma and ocular hypertension
9) Confidence 0.05 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701126 Disease Relevance 1.90 Pain Relevance 0.10
The studies used various end-point parameters including mean IOP reduction, %IOP reduction (%IOPR) from baseline, or target IOP levels.
Negative_regulation (reduction) of Gene_expression (reduction) of IOP associated with ocular hypertension
10) Confidence 0.03 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2915861 Disease Relevance 0.97 Pain Relevance 0
The studies used various end-point parameters including mean IOP reduction, %IOP reduction (%IOPR) from baseline, or target IOP levels.
Negative_regulation (reduction) of Gene_expression (reduction) of IOP associated with ocular hypertension
11) Confidence 0.03 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2915861 Disease Relevance 0.98 Pain Relevance 0
The studies used various end-point parameters including mean IOP reduction, %IOP reduction (%IOPR) from baseline, or target IOP levels.
Negative_regulation (reduction) of Gene_expression (reduction) of IOP associated with ocular hypertension
12) Confidence 0.03 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2915861 Disease Relevance 0.98 Pain Relevance 0
An inadequate IOP decrease (IOP>21 mmHg) was detected in 25 eyes (26.3%) on the first postoperative day with a mean IOP in these eyes of 34.9 mmHg.
Negative_regulation (decrease) of Gene_expression (detected) of IOP in eyes associated with ocular hypertension
13) Confidence 0.03 Published 2009 Journal Korean Journal of Ophthalmology : KJO Section Body Doc Link PMC2694298 Disease Relevance 1.55 Pain Relevance 0
An inadequate IOP decrease (IOP>21 mmHg) was detected in 25 eyes (26.3%) on the first postoperative day with a mean IOP in these eyes of 34.9 mmHg.
Negative_regulation (decrease) of Gene_expression (detected) of IOP in eyes associated with ocular hypertension
14) Confidence 0.03 Published 2009 Journal Korean Journal of Ophthalmology : KJO Section Body Doc Link PMC2694298 Disease Relevance 1.52 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox